{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:06:49Z","timestamp":1751342809144,"version":"3.41.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/V026917\/1","EP\/V026917\/1","EP\/V026917\/1","EP\/V026917\/1"],"award-info":[{"award-number":["EP\/V026917\/1","EP\/V026917\/1","EP\/V026917\/1","EP\/V026917\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Synthetic cannabinoids (SCs) are prevalent in prisons and among people who experience homelessness in the UK and can cause serious harms to people who use them. While it is currently not possible to test for SCs at the point of care (POC), a new method for doing so using fluorescence spectral fingerprinting has recently been developed. In this study, we aimed to outline the potential utility of POC SC testing in settings where SCs and SC use occur.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a mixed-methods study. Professional stakeholders (<jats:italic>n<\/jats:italic>\u2009=\u2009449) working or volunteering in healthcare, homeless, police, or prison services were invited to give their views on POC SC testing in an online survey with both quantitative and qualitative (free text) questions. Follow-up interviews were conducted with 35 survey participants and additionally with 25 people who use synthetic cannabinoids (PWUSC). Quantitative survey responses on the overall view of saliva- or drug-based detection of SCs were compared between the four groups using Kruskal-Wallis tests. Qualitative survey responses were analysed using content analysis and interviews were analysed using thematic analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>SCs were perceived as prevalent in UK prisons and homeless communities, but stakeholders felt poorly equipped to tackle SC use and harms. The quantitative analyses revealed that all groups rated both saliva- and drug-based detection positively, but police and prison services were more positive towards both types of testing than healthcare and homeless services (all <jats:italic>p\u2019s<\/jats:italic>\u2009&lt;\u20090.001). The thematic and content analyses outlined several potential benefits of POC SC testing across all four settings, with the strongest support for use in prisons, particularly to reduce the ingress of SCs. Both PWUSC and professional stakeholders raised concerns that testing would be used in a punitive manner and highlighted the lack of treatment options for SC dependence and overdose as a major barrier to reducing harms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>POC SC testing has the potential to support healthcare, homeless, police, and prison services in reducing the prevalence of SCs and improving the care of PWUSC. However, ethical application of the technology must be carefully considered to avoid causing undue harm to PWUSC, such as criminalisation and stigma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12954-025-01227-7","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:28:22Z","timestamp":1751279302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The utility of a new point-of-care test for synthetic cannabinoids: a mixed-methods study in people who use synthetic cannabinoids and stakeholders"],"prefix":"10.1186","volume":"22","author":[{"given":"Martine","family":"Skumlien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Craft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navyaa","family":"Toshniwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Pudney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom P.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"1227_CR1","unstructured":"Abdulrahim D, Bowden-Jones O. Harms of synthetic cannabinoid receptor agonists (SCRAs) and their management. London, UK; 2016."},{"issue":"8","key":"1227_CR2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/jat\/bkt068","volume":"37","author":"R Kronstrand","year":"2013","unstructured":"Kronstrand R, Roman M, Andersson M, Eklund A. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol. 2013;37(8):534\u201341.","journal-title":"J Anal Toxicol"},{"issue":"5","key":"1227_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00213-021-05945-1","volume":"239","author":"S Craft","year":"2022","unstructured":"Craft S, Ferris JA, Barratt MJ, Maier LJ, Lynskey MT, Winstock AR, et al. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. Psychopharmacology. 2022;239(5):1349\u201357.","journal-title":"Psychopharmacology"},{"key":"1227_CR4","volume-title":"European drug report: trends and developments","author":"EMCDDA","year":"2024","unstructured":"EMCDDA. European drug report: trends and developments. Luxembourg: Luxembourg; 2024."},{"key":"1227_CR5","unstructured":"Office for National Statistics. Drug misuse in England and Wales: year ending March 2023. 2023."},{"key":"1227_CR6","doi-asserted-by":"publisher","first-page":"104219","DOI":"10.1016\/j.drugpo.2023.104219","volume":"122","author":"S Craft","year":"2023","unstructured":"Craft S, Austin A, Tooth T, Glover C, Garrett T, Blagbrough IS, et al. Synthetic cannabinoid use in an adult male prison in the UK. Int J Drug Policy. 2023;122:104219.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1227_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/00952990.2016.1240799","volume":"43","author":"AM Joseph","year":"2017","unstructured":"Joseph AM, Manseau MW, Lalane M, Rajparia A, Lewis CF. Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting. Am J Drug Alcohol Abuse. 2017;43(1):117\u201322.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1227_CR8","unstructured":"MacLeod K, Pickering L, Gannon M, Greenwood S, Liddell D, Smith A et al. Understanding the patterns of use, motives, and harms of New Psychoactive Substances in Scotland. Edinburgh, UK; 2016."},{"issue":"4","key":"1227_CR9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/can.2020.0161","volume":"7","author":"P Yoganathan","year":"2022","unstructured":"Yoganathan P, Claridge H, Chester L, Englund A, Kalk NJ, Copeland CS. Synthetic cannabinoid-related deaths in England, 2012\u20132019. Cannabis Cannabinoid Res. 2022;7(4):516\u201325.","journal-title":"Cannabis Cannabinoid Res"},{"key":"1227_CR10","doi-asserted-by":"crossref","unstructured":"Duke K, Gleeson H, MacGregor S, Thom B. The risk matrix: Drug-related deaths in prisons in England and Wales, 2015\u20132020. J Community Psychol. 2023.","DOI":"10.1002\/jcop.22989"},{"issue":"1","key":"1227_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/08897077.2019.1686725","volume":"43","author":"JT Ellsworth","year":"2022","unstructured":"Ellsworth JT. Spice, vulnerability, and victimization: synthetic cannabinoids and interpersonal crime victimization among homeless adults. Subst Abus. 2022;43(1):32\u20138.","journal-title":"Subst Abus"},{"key":"1227_CR12","unstructured":"User Voice. Spice: the bird killer - what prisoners thing about the use of spice and other legal highs in prison. London, UK; 2016."},{"issue":"2","key":"1227_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/09595230500102434","volume":"24","author":"R Room","year":"2005","unstructured":"Room R. Stigma, social inequality and alcohol and drug use. Drug Alcohol Rev. 2005;24(2):143\u201355.","journal-title":"Drug Alcohol Rev"},{"key":"1227_CR14","doi-asserted-by":"crossref","unstructured":"Cozier G, Gardner M, Craft S, Skumlien M, Spicer J, Andrews R et al. Synthetic cannabinoids consumed via e-cigarettes in English schools. medRxiv. 2024.","DOI":"10.1101\/2024.08.12.24311617"},{"key":"1227_CR15","doi-asserted-by":"crossref","unstructured":"Craft S, Sunderland P, Millea MF, Pudney CR, Sutcliffe OB, Freeman TP. Detection and quantification of synthetic cannabinoids in seven illicitly sourced disposable vapes submitted by an individual presenting to a UK drug and alcohol service. Addiction. 2024.","DOI":"10.1111\/add.16671"},{"key":"1227_CR16","doi-asserted-by":"publisher","first-page":"e076611","DOI":"10.1136\/bmj-2023-076611","volume":"382","author":"M Skumlien","year":"2023","unstructured":"Skumlien M, Craft S, Scott J, Freeman TP. Turning down the Spice: tackling the problems of synthetic cannabinoids. BMJ. 2023;382:e076611.","journal-title":"BMJ"},{"issue":"20","key":"1227_CR17","doi-asserted-by":"publisher","first-page":"12971","DOI":"10.1021\/acs.analchem.9b03037","volume":"91","author":"B May","year":"2019","unstructured":"May B, Naqi HA, Tipping M, Scott J, Husbands SM, Blagbrough IS, et al. Synthetic cannabinoid receptor agonists detection using fluorescence spectral fingerprinting. Anal Chem. 2019;91(20):12971\u20139.","journal-title":"Anal Chem"},{"key":"1227_CR18","doi-asserted-by":"crossref","unstructured":"Gardner M, Bowden C, Manzoor S, Cozier G, Andrews R, Craft S et al. Automated detection of controlled substances from sealed e-cigarettes. ChemRxiv. 2024.","DOI":"10.26434\/chemrxiv-2024-ns335"},{"key":"1227_CR19","doi-asserted-by":"crossref","unstructured":"Power A, Gardner M, Andrews R, Cozier G, Kumar R, Freeman TP et al. A field-portable technology for illicit drug discrimination via deep learning of hybridized reflectance\/fluorescence spectro-scopic fingerprints. ChemRxiv. 2024.","DOI":"10.26434\/chemrxiv-2024-f5tq3-v2"},{"issue":"37","key":"1227_CR20","doi-asserted-by":"publisher","first-page":"13829","DOI":"10.1021\/acs.analchem.3c01844","volume":"95","author":"GE Cozier","year":"2023","unstructured":"Cozier GE, Andrews RC, Frinculescu A, Kumar R, May B, Tooth T, et al. Instant detection of synthetic cannabinoids on physical matrices, implemented on a Low-Cost, ultraportable device. Anal Chem. 2023;95(37):13829\u201337.","journal-title":"Anal Chem"},{"issue":"4","key":"1227_CR21","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/dta.2767","volume":"12","author":"C Norman","year":"2020","unstructured":"Norman C, Walker G, McKirdy B, McDonald C, Fletcher D, Antonides LH, et al. Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market. Drug Test Anal. 2020;12(4):538\u201354.","journal-title":"Drug Test Anal"},{"key":"1227_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","volume":"6","author":"S Michie","year":"2011","unstructured":"Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.","journal-title":"Implement Sci"},{"issue":"4","key":"1227_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1017\/jsc.2017.25","volume":"13","author":"T Sharpe","year":"2018","unstructured":"Sharpe T, Alsahlanee A, Ward KD, Doyle F. Systematic review of clinician-reported barriers to provision of smoking cessation interventions in hospital inpatient settings. J Smok Cessat. 2018;13(4):233\u201343.","journal-title":"J Smok Cessat"},{"issue":"1","key":"1227_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12888-019-2029-3","volume":"19","author":"CA Smith","year":"2019","unstructured":"Smith CA, McNeill A, Kock L, Shahab L. Exploring mental health professionals\u2019 practice in relation to smoke-free policy within a mental health trust: a qualitative study using the COM-B model of behaviour. BMC Psychiatry. 2019;19(1):54.","journal-title":"BMC Psychiatry"},{"key":"1227_CR25","unstructured":"Skumlien M, Scott J, Freeman TP. Understanding stakeholder views on a novel point-of-care detection device for synthetic cannabinoid receptor agonists (SCRAs): Open Science Framework; 2023 [Available from: https:\/\/osf.io\/3z6ja\/]."},{"issue":"13","key":"1227_CR26","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360.","journal-title":"Qual Health Res"},{"key":"1227_CR27","volume-title":"R: A Language and environment for statistical computing","author":"R Core Team","year":"2019","unstructured":"R Core Team. R: A Language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019."},{"key":"1227_CR28","unstructured":"Braun V, Clarke V. Successful qualitative research: A practical guide for beginners. Sage; 2013."},{"issue":"3","key":"1227_CR29","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/add.15734","volume":"117","author":"N Maghsoudi","year":"2022","unstructured":"Maghsoudi N, Tanguay J, Scarfone K, Rammohan I, Ziegler C, Werb D, et al. Drug checking services for people who use drugs: a systematic review. Addiction. 2022;117(3):532\u201344.","journal-title":"Addiction"},{"key":"1227_CR30","unstructured":"Brunt T. Drug checking as a harm reduction tool for recreational drug users: opportunities and challenges. 2017."},{"key":"1227_CR31","unstructured":"Carver H, Falzon D, Parkes T, Nicholls J. Assessing the need for, and views on, drug checking services in Edinburgh. Edinburgh, UK; 2023."},{"issue":"3","key":"1227_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1017\/S1461145713001247","volume":"17","author":"JB Zawilska","year":"2014","unstructured":"Zawilska JB, Wojcieszak J. Spice\/K2 drugs\u2013more than innocent substitutes for marijuana. Int J Neuropsychopharmacol. 2014;17(3):509\u201325.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1227_CR33","doi-asserted-by":"publisher","first-page":"103305","DOI":"10.1016\/j.drugpo.2021.103305","volume":"97","author":"R Ralphs","year":"2021","unstructured":"Ralphs R, Gray P, Sutcliffe OB. The impact of the 2016 psychoactive substances act on synthetic cannabinoid use within the homeless population: markets, content and user harms. Int J Drug Policy. 2021;97:103305.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"1227_CR34","first-page":"e40736","volume":"15","author":"J Pergolizzi Jr","year":"2023","unstructured":"Pergolizzi J Jr., Raffa R, LeQuang JAK, Breve F, Varrassi G. Old drugs and new challenges: A narrative review of nitazenes. Cureus. 2023;15(6):e40736.","journal-title":"Cureus"},{"key":"1227_CR35","doi-asserted-by":"publisher","first-page":"103512","DOI":"10.1016\/j.drugpo.2021.103512","volume":"100","author":"A McAuley","year":"2022","unstructured":"McAuley A, Matheson C, Robertson JR. From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic. Int J Drug Policy. 2022;100:103512.","journal-title":"Int J Drug Policy"},{"key":"1227_CR36","doi-asserted-by":"publisher","first-page":"103112","DOI":"10.1016\/j.drugpo.2021.103112","volume":"93","author":"BE Meyerson","year":"2021","unstructured":"Meyerson BE, Russell DM, Kichler M, Atkin T, Fox G, Coles HB. I don\u2019t even want to go to the Doctor when I get sick now: healthcare experiences and discrimination reported by people who use drugs, Arizona 2019. Int J Drug Policy. 2021;93:103112.","journal-title":"Int J Drug Policy"},{"issue":"27","key":"1227_CR37","first-page":"464","volume":"106","author":"US Zimmermann","year":"2009","unstructured":"Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of spice gold. Dtsch Arztebl Int. 2009;106(27):464\u20137.","journal-title":"Dtsch Arztebl Int"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01227-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01227-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01227-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:28:25Z","timestamp":1751279305000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01227-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01227-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the University of Bath Research Ethics Committee (EP 22 024; 0316\u2013405) and from the HMPPS National Research Committee (2023\u2009\u2212\u2009303). All participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants consented to anonymised quotes being shared in research outputs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS has delivered educational seminars for Gilead and Ethypharm but received no financial reimbursement for these. JS also works as a clinician for a drug and alcohol treatment provider, but no recruitment was undertaken of people for whom she has clinical responsibility. Remaining authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}